Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Blood|October 15, 1996
Different CD44 splicing patterns define prognostic subgroups in multiple myelomaR Stauder, M Van Driel, C Schwärzler, et al.
Seminars in Oncology|April 1, 1992
A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinomaE D Kreuser, R U Hilgenfeld, M Matthias, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 4, 2008
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatmentM Kornmann, A Formentini, C Ette, et al.
Klinische Wochenschrift|April 3, 1989
[Reversible germ cell toxicity following aggressive chemotherapy in patients with testicular tumors: results of a prospective study]E D Kreuser, E Kurrle, W D Hetzel, et al.
Onkologie|February 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment GroupD Peest, H Deicher, R Coldewey, et al.
Cancer Treatment Reviews|September 1, 1990
High-intensity therapy versus low-intensity therapy in advanced breast cancer patientsF Porzsolt, E D Kreuser, G Meuret, et al.
Seminars in Oncology|April 1, 1992
A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinomaE D Kreuser, R U Hilgenfeld, M Matthias, et al.
International Journal of Cancer|April 9, 1998
De novo expression of the alpha5beta1-fibronectin receptor in HT29 colon-cancer cells reduces activity of C-SRC. Increase of C-SRC activity by attachment on fibronectinR Schmidt, M Streit, R Kaiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO)H J Weh, H J Wilke, J Dierlamm, et al.
Onkologie|November 6, 2001
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancerG Hartung, R D Hofheinz, A Wein, et al.
Pageof 7